

Discussions with leaders: Kostakoglu talks with Vincent Rajkumar, MD, from the Mayo clinic, about collaborative and pioneering work in establishing influential guidelines in the treatment of myeloma. **Page 831**

¹⁸F-labeled SSTR tracers: Leupe and colleagues provide an update of currently available clinical data regarding ¹⁸F-labeled somatostatin analog tracers and justification for clinical applications. **Page 835**

PET/CT and osteosarcoma management: Oh and colleagues offer an educational overview of clinical aspects of osteosarcoma management and assess the role of ¹⁸F-FDG PET/CT, with special focus on pediatric and young adult patients. **Page 842**

¹⁸F-Fluciclovine PET in glioblastoma: Nabavizadeh and colleagues report on a study assessing the value of ¹⁸F-fluciclovine PET for differentiating pseudoprogression from tumor progression in patients with suspected radiographic recurrence of glioblastoma. **Page 852**

⁶⁸Ga-DOTA-MGS5 PET/CT in MTC: von Guggenberg and colleagues describe imaging results with this ⁶⁸Ga-labeled minigastrin analog to evaluate cholecystokinin-2 receptor expression status and local recurrence/metastases in patients with advanced medullary thyroid cancer. **Page 859**

Imaging tumor status in prostate cancer: al Jalali and colleagues explore the use of [⁶⁸Ga]PSMA and [¹⁸F]FDHT in PET imaging as a potential substitute for analysis of prostate cancer tumors, particularly in evaluating androgen receptor expression. **Page 863**

Patient-reported outcomes for PC: Gudenkauf and colleagues detail development of a patient-reported outcome measure for radionuclide therapy in prostate cancer, with utility as a standardized tool to monitor relevant symptoms and toxicities. **Page 869**

Signaling network response to TAT: Qin and colleagues investigate cellular responses to targeted α -particle therapy and demonstrate the radiosensitizing potential of histone deacetylase inhibitors for ²²⁵Ac-PP-F11N in cholecystokinin B receptor-positive tumors. **Page 873**

PRRT in high liver tumor burden: Gococo-Benore and colleagues assess the risk of hepatotoxicity for patients with gastroenteropancreatic neuroendocrine tumors and very high liver tumor burden undergoing peptide-receptor radionuclide therapy. **Page 880**

¹²⁴I-MIBG dosimetry-guided ¹³¹I-MIBG therapy: Maric and colleagues report on the efficacy and safety of ¹²⁴I-MIBG dosimetry-guided high-activity ¹³¹I-MIBG therapy in patients with advanced pheochromocytoma or neuroblastoma. **Page 885**

PSMA dosimetry in HGG: Graef and colleagues investigate [¹⁷⁷Lu]Lu-PSMA therapy in high-grade glioma, with a focus on intratherapeutic dosimetry. **Page 892**

PSMA PET/CT criteria and prognosis: Lunger and colleagues explore the prognostic utility of conventional biochemical/imaging response criteria and ⁶⁸Ga-PSMA11 PET-based criteria for overall survival in metastatic hormone-sensitive and castration-resistant prostate cancer treated with taxane-based chemotherapy. **Page 896**

⁶⁸Ga-PSMA PET for PB recurrence SRT: Sonni and colleagues use ⁶⁸Ga-PSMA-11 PET/CT to evaluate patterns of prostate bed recurrence and guide salvage radiotherapy in prostate-specific antigen persistence or biochemical recurrence after radical prostatectomy. **Page 902**

PSMA expression in CRPC: Calderoni and colleagues examine PSMA expression in patients with castration-resistant prostate cancer and compare PET/CT response with prostate-specific antigen variation as a prognostic factor for progression-free and overall survival. **Page 910**

PSMA-positive LNs and ENRT templates: Trapp and colleagues analyze PSMA PET/CT-positive lymph nodes and compare results with those from several templates proposed for salvage elective nodal radiotherapy, emphasizing the role of imaging in individualization of treatment. **Page 918**

[²²⁵Ac]Ac-ofatumumab and lymphoma: Longtine et al and colleagues describe preparation of ²²⁵Ac-labeled anti-CD20 ofatumumab and evaluate its in vitro characteristics and therapeutic efficacy in a murine model of disseminated human lymphoma. **Page 924**

Strain analysis from ECG-gated PET MPI: Huang and colleagues detail development of a measure of longitudinal, radial, and circumferential myocardial strain at rest and during pharmacologic stress using ⁸²Rb PET electrocardiography-gated myocardial perfusion imaging. **Page 932**

PET and pulmonary fibrosis: Isser and colleagues use a ⁶⁴Cu-labeled platelet glycoprotein VI fusion protein targeting extracellular matrix fibers as a PET tracer to observe longitudinal remodeling in

a bleomycin-induced pulmonary fibrosis mouse model. **Page 940**

Pretreatment ¹³¹I-omburtamab imaging and dosimetry: Pandit-Taskar and colleagues perform ¹³¹I-omburtamab imaging and dosimetric analysis for estimation of absorbed dose to the cerebrospinal fluid compartment before ¹³¹I-omburtamab therapy for leptomeningeal disease. **Page 946**

AI-denoised low-dose ⁶⁴Cu-DOTATATE PET: Loft and colleagues ask whether artificial intelligence approaches can be used to restore visual quality and lesion detection in PET images acquired with <50 MBq of ⁶⁴Cu-DOTATATE in patients with neuroendocrine neoplasms. **Page 951**

Total-body ⁶⁸Ga-FAPI parametric imaging: Chen and colleagues explore the pharmacokinetics of ⁶⁸Ga-FAPI-04 PET/CT in pancreatic and gastric cancer and conduct parametric imaging of dynamic total-body data compared with SUV-based imaging. **Page 960**

Perfusion index with [¹⁸F]MK6240: Guehl and colleagues research the potential utility of the early phase of imaging with [¹⁸F]MK6240, with high affinity and selectivity for hyperphosphorylated tau, as a surrogate index of cerebral perfusion. **Page 968**

Explainable AI: Bradshaw and colleagues summarize key arguments for and against the use of “explainable artificial intelligence” from the perspectives of data science, clinical practice, and bioethics. **Page 976**

Ultrahigh-resolution small-animal PET: Kang and colleagues report on an ultrahigh-resolution small-animal PET scanner that can provide a resolution approaching 0.6 mm to visualize mouse brain function and serve as a promising molecular imaging tool for neuroscience research. **Page 978**

Theranostic radiopharmaceuticals: Urban and colleagues review currently available education and accreditation offerings and policies for theranostics around the world and discuss educational and proficiency challenges. **Page 986**

⁶⁸Ga-FAPI-46 urachal remnant: Maliha and colleagues present an example of potentially confounding incidental uptake in a urachal remnant on preoperative ⁶⁸Ga-FAPI-46 PET/CT. **Page 992**

Incidental bronchial findings on ¹⁸F-PSMA PET/CT: Orciuolo and colleagues describe a case of large-airway PSMA localization in a patient with chronic airway inflammation, highlighting the potential for false-positive findings. **Page 993**